These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 10163420)

  • 1. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ; Goa KL
    Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
    Hawkins DW; Langley PC; Krueger KP
    Am J Health Syst Pharm; 1997 May; 54(10):1185-90. PubMed ID: 9161627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
    Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
    Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
    Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
    Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
    Dunn CJ; Jarvis B
    Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
    Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
    Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
    Reeves P; Cooke J; Lloyd A; Hutchings A
    Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
    Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
    Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
    Hawkins DW; Langley PC; Krueger KP
    Clin Ther; 1998; 20(1):182-95. PubMed ID: 9522114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
    Bergqvist D
    Pharmacoeconomics; 2002; 20(4):225-43. PubMed ID: 11950380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with bemiparin.
    Abad Rico JI; Lozano Sánchez FS; Rocha E
    Drugs; 2010 Dec; 70 Suppl 2():25-33. PubMed ID: 21162607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
    Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
    Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.